About
Fong is an independent consultant and Adjunct Associate Professor at Queen's University specializing in gene therapy. At BioMarin she led development of the first approved AAV-based gene therapy for hemophilia A.
Colleagues at Pathway to Cures
Amy L. Dunn
Chair, Medical and Scientific Advisory Council (MASAC) for NBDF at Pathway to Cures
Beth Whitehouse
NBDF Senior Vice President for Advancement at Pathway to Cures
Brian Andrew
Investment Committee Chair at Pathway to Cures
Christine Brennan
Investment Committee Member at Pathway to Cures
Geeta Vemuri
Managing Partner, Founder at Agent Capital
Gilbert C. White
P2C Board Vice Chair & Secretary at Pathway to Cures
Gilbert C. White, II
P2C Board Vice Chair & Secretary at Pathway to Cures
Glenn Pierce
Scientific Advisory Group Co-Chair at Pathway to Cures
Frequently asked questions
- Who is Sylvia Fong?
- Fong is an independent consultant and Adjunct Associate Professor at Queen's University specializing in gene therapy. At BioMarin she led development of the first approved AAV-based gene therapy for hemophilia A.
- Where does Sylvia Fong work?
- Sylvia Fong is Scientific Advisory Group Member at Pathway to Cures.